Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C36H49Cl2N6O6S.Cl |
Molecular Weight | 800.235 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].CC1=NC2=C(C=CC=C2OCC3=C(Cl)C=CC(=C3Cl)S(=O)(=O)NC4(CCOCC4)C(=O)N5CCN(CC5)C(=O)[C@@H](N)CCC[N+](C)(C)C)C(C)=C1
InChI
InChIKey=ZNHJDJYKDVGQSH-JMAPEOGHSA-M
InChI=1S/C36H49Cl2N6O6S.ClH/c1-24-22-25(2)40-33-26(24)8-6-10-30(33)50-23-27-28(37)11-12-31(32(27)38)51(47,48)41-36(13-20-49-21-14-36)35(46)43-17-15-42(16-18-43)34(45)29(39)9-7-19-44(3,4)5;/h6,8,10-12,22,29,41H,7,9,13-21,23,39H2,1-5H3;1H/q+1;/p-1/t29-;/m0./s1
Fasitibant (MEN-16132) is a non-peptide sulfonamide-containing bradykinin hB2 receptor antagonist. It inhibits pro-inflammatory response in vitro and alleviates inflammatory hyperalgesia in rodent models of osteoarthritis. Menarini Group was developing fasitibant for the treatment of osteoarthritis. Fasitibant development has been discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02205814
Unknown
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22638761
Incubation of synoviocytes with BK induced a sustained production of PGE(2) and transient COX-2 gene expression that were prevented by pretreatment with fasitibant (1 μM, 30 min preincubation).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11535140
Created by
admin on Fri Dec 15 20:13:24 GMT 2023 , Edited by admin on Fri Dec 15 20:13:24 GMT 2023
|
PRIMARY | |||
|
DBSALT002945
Created by
admin on Fri Dec 15 20:13:24 GMT 2023 , Edited by admin on Fri Dec 15 20:13:24 GMT 2023
|
PRIMARY | |||
|
7J764K70IG
Created by
admin on Fri Dec 15 20:13:24 GMT 2023 , Edited by admin on Fri Dec 15 20:13:24 GMT 2023
|
PRIMARY | |||
|
1157852-02-2
Created by
admin on Fri Dec 15 20:13:24 GMT 2023 , Edited by admin on Fri Dec 15 20:13:24 GMT 2023
|
PRIMARY | |||
|
100000175071
Created by
admin on Fri Dec 15 20:13:24 GMT 2023 , Edited by admin on Fri Dec 15 20:13:24 GMT 2023
|
PRIMARY | |||
|
9256
Created by
admin on Fri Dec 15 20:13:24 GMT 2023 , Edited by admin on Fri Dec 15 20:13:24 GMT 2023
|
PRIMARY | |||
|
C167030
Created by
admin on Fri Dec 15 20:13:24 GMT 2023 , Edited by admin on Fri Dec 15 20:13:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL218427
Created by
admin on Fri Dec 15 20:13:24 GMT 2023 , Edited by admin on Fri Dec 15 20:13:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD